drugset / Trial / NCT02464878
Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant
Phase 2
Completed
2 enrolled
Massachusetts General Hospital
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · collabUniversity of Iowa · collab
NaSingle-groupOpen-labelTreatment
Summary
Patients meeting the study entry criteria will receive 1-3 infusion(s) of in vitro cultured islets. Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
Timeline
- Start
- 2017-01
- Primary completion
- 2022-11
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alpha 1-Antitrypsin | Protein / enzyme biologic | — | — |
| Background | Basiliximab | Monoclonal antibody | — | — |
| Background | Etanercept | Protein / enzyme biologic | — | — |
| Background | Thymoglobulin | Protein / enzyme biologic | — | — |